The Myriad Collaborative Research Registry advances patient care by combining structured clinical data with genetic and genome testing. The overarching goal is to create an environment for improving and advancing cancer care.
If you would like to access the registry, please include your contact information and someone from our team will contact you soon.
Contact Information
The registry is pre-loaded with de-identified data on >1.1 million patients. This includes genetic and genome results along with clinical components from test requisition forms (TRF). Numerous Myriad tests are included across multiple cancer types. Immediate data exploration is available for researchers who have been trained on the MCRR dashboard.
Once access is granted to the research portal, users will be able to carry out queries and analyses that will help inform and foster research opportunities.
Some examples include:
The trainer orienting you to MCRR dashboard is available for support to navigate the registry. Contact [email protected] for triage to other experts as appropriate.
Germline(FDA-Approved)
Germline(Non-FDA-Approved)
HRD†status(FDA-Approved)
Tumor profiling†status(Non-FDA-Approved)
† For patients with ovarian cancer‡Precise™ Tumor is powered by Intermountain Precision Genomics, a service of Intermountain® Healthcare
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
Learn more